Cited Articles for PMCID: 2623290

Year	Number of Results
1976	1
1979	2
1980	1
1981	2
1983	2
1984	2
1985	7
1986	2
1987	4
1988	4
1989	4
1990	2
1991	6
1992	6
1993	8
1994	5
1995	8
1996	4
1997	8
1998	10
1999	7
2000	11
2001	2
2002	19
2003	25
2004	16
2005	11
2024	0

1

Heterogeneous tumor evolution initiated by loss of pRb function in a preclinical prostate cancer model.

Hill R, Song Y, Cardiff RD, Van Dyke T. Hill R, et al. Cancer Res. 2005 Nov 15;65(22):10243-54. doi: 10.1158/0008-5472.CAN-05-1579. Cancer Res. 2005. PMID: 16288012

2

Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer.

Macleod K, Mullen P, Sewell J, Rabiasz G, Lawrie S, Miller E, Smyth JF, Langdon SP. Macleod K, et al. Cancer Res. 2005 Aug 1;65(15):6789-800. doi: 10.1158/0008-5472.CAN-04-2684. Cancer Res. 2005. PMID: 16061661

3

In pursuit of effective toxicogenomics.

Gant TW, Zhang SD. Gant TW, et al. Mutat Res. 2005 Aug 4;575(1-2):4-16. doi: 10.1016/j.mrfmmm.2005.02.007. Mutat Res. 2005. PMID: 15885710 Review.

4

Butyrate response factor 1 enhances cisplatin sensitivity in human head and neck squamous cell carcinoma cell lines.

Lee SK, Kim SB, Kim JS, Moon CH, Han MS, Lee BJ, Chung DK, Min YJ, Park JH, Choi DH, Cho HR, Park SK, Park JW. Lee SK, et al. Int J Cancer. 2005 Oct 20;117(1):32-40. doi: 10.1002/ijc.21133. Int J Cancer. 2005. PMID: 15880358 Free article.

5

Differentiating mechanisms of toxicity using global gene expression analysis in Saccharomyces cerevisiae.

Caba E, Dickinson DA, Warnes GR, Aubrecht J. Caba E, et al. Mutat Res. 2005 Aug 4;575(1-2):34-46. doi: 10.1016/j.mrfmmm.2005.02.005. Mutat Res. 2005. PMID: 15878181

6

Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling.

Takata R, Katagiri T, Kanehira M, Tsunoda T, Shuin T, Miki T, Namiki M, Kohri K, Matsushita Y, Fujioka T, Nakamura Y. Takata R, et al. Clin Cancer Res. 2005 Apr 1;11(7):2625-36. doi: 10.1158/1078-0432.CCR-04-1988. Clin Cancer Res. 2005. PMID: 15814643 Clinical Trial.

7

Cellular processing of platinum anticancer drugs.

Wang D, Lippard SJ. Wang D, et al. Nat Rev Drug Discov. 2005 Apr;4(4):307-20. doi: 10.1038/nrd1691. Nat Rev Drug Discov. 2005. PMID: 15789122 Review.

8

Overexpression of genes on 16q associated with cisplatin resistance of testicular germ cell tumor cell lines.

Wilson C, Yang J, Strefford JC, Summersgill B, Young BD, Shipley J, Oliver T, Lu YJ. Wilson C, et al. Genes Chromosomes Cancer. 2005 Jun;43(2):211-6. doi: 10.1002/gcc.20173. Genes Chromosomes Cancer. 2005. PMID: 15761863

9

Establishment and gene analysis of a cisplatin-resistant cell line, Sa-3R, derived from oral squamous cell carcinoma.

Nakatani K, Nakamura M, Uzawa K, Wada T, Seki N, Tanzawa H, Fujita S. Nakatani K, et al. Oncol Rep. 2005 Apr;13(4):709-14. Oncol Rep. 2005. PMID: 15756446

10

Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells.

Roberts D, Schick J, Conway S, Biade S, Laub PB, Stevenson JP, Hamilton TC, O'Dwyer PJ, Johnson SW. Roberts D, et al. Br J Cancer. 2005 Mar 28;92(6):1149-58. doi: 10.1038/sj.bjc.6602447. Br J Cancer. 2005. PMID: 15726096 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

176 results

Results by year